AxioMx is applying knowledge gained from the past 15 years of human genome sequencing to produce highly specific recombinant antibodies against the human proteome. The existing antibody development paradigm is too slow and does not always result in consistent, renewable, and quality antibodies. Through proprietary advances in traditional phage display antibody library design, phage display screening and affinity maturation technologies, we rapidly generate antibodies at the required binding and specificity criteria. At AxioMx, we believe our platform will lead to the wide adoption of recombinant antibody use in research and diagnostic applications.
Our methods have shortened traditional monoclonal antibody development times from months to weeks and enable fast delivery of highly specific, high affinity, and highly reproducible recombinant monoclonal antibodies that are optimized to work in a desired application.